Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
Open Access
- 14 January 1999
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 79 (3-4) , 509-514
Abstract
Marimastat is a specific inhibitor of matrix metalloproteinases that has been shown to be effective in cancer models. A pilot, escalating-dose study of oral marimastat was performed in patients with recurrent colorectal cancer, in whom evaluation of serological response was made by measurement of carcinoembryonic antigen (CEA) levels. The study assessed the safety and tolerability of 4 weeks administration of marimastat, and determined a dose range producing detectable serological effects. Patients were recruited with a serum CEA level greater than 5 ng ml–1, and rising by more than 25% over a 4-week screening period. Patients were treated for 28 days and entered into a continuation protocol if a serological response or clinical benefit was observed. Pharmacokinetic and safety data determined that groups of patients were recruited sequentially at 25 mg and 50 mg twice daily, and, thereafter, 10 mg twice daily, 10 mg once daily, 5 mg once daily and 20 mg once daily. A biological effect (BE) was defined as a CEA value on day 28 no greater than on day 0; a partial biological effect (PBE) was defined as a rise in CEA over the 28-day treatment period of less than 25%. Of 70 patients recruited, 63 completed the 28-day treatment period, and 55 were eligible for cancer antigen analysis. Examination of the dose–effect relationships provides evidence for a causal relationship between marimastat and biological effects: the proportion of patients with BE or PBE was higher with twice daily dosing (16 out of 25, 64%) than with once daily dosing (11 out of 30, 37%) (P = 0.043, χ2 test). Furthermore, the median rates of rise of CEA fell markedly during treatment compared with the screening period for patients receiving twice daily marimastat (P < 0.0001), but not for patients receiving marimastat once daily (P = 0.25). Musculoskeletal adverse events emerged as the principal drug-related toxicity of marimastat, occurring in a dose- and time-dependent fashion. It was concluded that marimastat was associated with dose-dependent biological effects in cancer patients. The occurrence of musculoskeletal side-effects define 25 mg twice daily as the upper limit of the dose range for continuous use in further studies. Therefore, a dose range of 20 mg once daily to 25 mg twice daily seems appropriate for further studies, which should aim to demonstrate the efficacy of the drug in terms of conventional clinical end points and describe the long-term tolerability of this novel agent.Keywords
This publication has 28 references indexed in Scilit:
- Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteersBritish Journal of Clinical Pharmacology, 1998
- Matrilysin is associated with progression of colorectal tumorCancer Letters, 1996
- Recent advances in matrix metalloproteinase inhibitor researchDrug Discovery Today, 1996
- Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniquesDiseases of the Colon & Rectum, 1996
- Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbitsInflammation Research, 1995
- Expression and localization of matrix‐degrading metalloproteinases during colorectal tumorigenesisMolecular Carcinogenesis, 1994
- Structural biochemistry and activation of matrix metalloproteasesCurrent Opinion in Cell Biology, 1993
- Metalloproteinases and their inhibitors in matrix remodelingTrends in Genetics, 1990
- Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer.Gut, 1987
- DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUESJournal of Experimental Medicine, 1965